Box, Inc. (NYSE:BOX), the leading Intelligent Content Management (ICM) platform, today announced a new set of AI-powered ...

Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort ...

Enveric's efforts are now focused on the development of EB-003, the Company's novel, potentially first-in-class, neuroplastogen, with the intention to file an Investigational New Drug application ...